News & Updates
Filter by Specialty:
Show Multimedia Only

Subcutaneous on par with IV pembrolizumab for NSCLC
20 hours ago
byStephen Padilla
Pembrolizumab administered subcutaneously (SC) is noninferior to the intravenous (IV) strategy in terms of overall exposure and trough concentrations, with similar efficacy and consistent safety profiles in patients with treatment-naive metastatic nonsmall cell lung cancer (NSCLC), reports a study.
Subcutaneous on par with IV pembrolizumab for NSCLC
20 hours ago
Esketamine monotherapy shows robust, rapid efficacy as treatment for TRD
a day ago
byMike Ng
Intranasal esketamine, administered at two fixed doses as monotherapy for treatment-resistant depression (TRD), has demonstrated robust and rapid efficacy in a phase IV double-blind, placebo-controlled randomized trial.